Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine Maintenance in AML (VIALE-M)
NCT04102020Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Mar 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04102020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102020.